Shopping Cart 0
Cart Subtotal
AED 0

Cardiovascular Pharmaceuticals Market in India 2012

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 3487

Details

Cardiovascular pharmaceuticals market in India is the second largest contributor to domestic pharmaceutical sales, contributing around 15.6%. Since India has a huge patient pool, the Indian market is characterized by a huge demand for cardiovascular drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the patient population, patent expiry of popular blockbuster drugs, increase in disposable income and introduction of newer and better drugs is helping the market to grow. The Indian Government, on its part has taken initiatives to reduce drug prices, has made certain reforms in the tax structure and has undertaken various control programmes. The market is expected to exhibit steady growth over the next few years.

The report begins with the introduction section which offers a brief insight into the major cardiovascular drug classes. It then moves to the market overview section which provides an insight into the global market and then moves on to the Indian market, highlighting the market size and growth.

An analysis of the drivers explains the factors for growth of the industry including increasing patient population, patent expiry of blockbuster drugs, increase in disposable income and introduction of newer and better drugs. The key challenges include strong competition between the different pharma companies and competition from complementary and alternative medicines.

The government initiatives section gives analyses the efforts to reduce drug prices, changes in the customs duty structure and the various control programmes undertaken by the Government.

A brief overview of the drug market value chain, drug regulations and patents is presented in the next section. It analyses the pharmaceutical value chain, and focuses on the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. A snapshot of different regulatory frameworks existing in the Indian pharma industry has been provided. The section also provides a list of important patent approvals for cardiovascular drugs.

The competition section gives overview of pharmaceutical companies in the country operating in the cardiovascular pharmaceutical industry. Thereafter, the report highlights the features of the major players operating in the market in detail. It includes elaborate profile of the major players in the market along with their financial analysis. Porters Five Forces Analysis has been incorporated for a brief but effective understanding of the market scenario. It also incorporates the recent developments in the Cardiovascular Pharmaceutical industry.

The strategic recommendations section focuses on some effective strategic decisions which can be taken up by companies to increase their market shares. The strategic recommendations section focuses on some effective strategic decisions which can be taken up by companies to increase their market shares. Foray into the preventive care therapeutic segment will help the companies gain a competitive advantage over the others. Companies can focus on development of such cardiovascular drugs which can be used as preventive medicines, but without any side effects. Also, efficient marketing strategies are required to make both the physicians and the patients aware of such preventive medicines.

READ MORE

Table Of Content

Scope

Page 1: Executive summary

Introduction

Page 2: Major drug classes of cardiovascular drugs

Market Overview

Page 3: Global Cardiovascular Pharmaceuticals Market-Overview, Size & Growth (Value: 2009-15e),

Page 4: Indian Cardiovascular Pharmaceuticals Market- Overview, Size & Growth (Value: 2010-2015e), Growth in Therapeutic segments

Drivers & Challenges

Page 5: Summary

Page 6-9: Drivers

Page 10: Challenges

Government Initiatives

Page 11: Summary

Page 12-13: Government Initiatives

Market value chain, regulation and patents

Page 14: Pharmaceutical value chain

Page 15: Phases of clinical trials

Page16-17: Drug regulations

Page 18: Regulatory frameworks

Page 19-20: List of patent approvals

Competition

Page 21- Market Competition-Porter's Five Forces Analysis

Page 22- 57: Major public players

Page 58- 69: Major private players

Page 70: Recent Developments

Strategic Recommendation

Page 71: Strategic Recommendations


List Of Figure

Market Overview

1. Cardiovascular Pharmaceutical Market- Global Market Size and Growth (Value wise 2009-2015e)

2. Cardiovascular Pharmaceutical Market-India Market Size and Growth (Value-Wise, 2010-2015e)

3. Top pharmaceutical segments (Percentage wise 2010)

Drivers & Challenges

4. Deaths from CVDs (Value wise 2000-2025e)

5. Coronary heart disease patients (Value wise 2010-2015e)

6. Increasing per capita disposable income ( Value wise 2007-2011)

Competition

7. Financial Snapshot

8. Key Business segments (only Public Players)

9. Key Geographic segments (only Public Players)

Except GlaxoSmithKline Pharmaceuticals Limited


List Of Table

Market Overview

1. Top selling cardiovascular drugs 2010-global market

Drivers & Challenges

2. Patent expiry date of drugs

Market Value Chain, Regulation and Patent

3. Tabular representation of drugs approved in recent past (2009- 2010)

4. Tabular representation of regulatory framework of Indian Pharmaceutical Industry

5. Tabular representation of USFDA patent approvals for cardiovascular drugs

Competition

6. Company profiles (All companies)

a. Company information

b. Products and services

c. Key people

d. Key Financial Performance Indicators

e. Key Ratios

Except for Pfizer Limited

f. Business Highlights

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

1. AstraZeneca Pharma India Limited

2. Aventis Pharma Limited

3. Cipla Limited

4. Dr. Reddy's Laboratories Limited

5. GlaxoSmithKline Pharmaceuticals Limited

6. Lupin Limited

7. Merck Limited

8. Novartis India Limited

9. Pfizer Limited

10. Ranbaxy Laboratories Limited

11. Sun Pharmaceutical Industries Limited

12. Torrent Pharmaceuticals Limited

13. Bristol-Myers Squibb India Private Limited

14. Cadila Pharmaceuticals Limited

15. Intas Pharmaceuticals Limited

16. USV Limited

Company Profile

Company Profile Title

Cardiovascular pharmaceuticals market in India is the second largest contributor to domestic pharmaceutical sales, contributing around 15.6%. Since India has a huge patient pool, the Indian market is characterized by a huge demand for cardiovascular drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the patient population, patent expiry of popular blockbuster drugs, increase in disposable income and introduction of newer and better drugs is helping the market to grow. The Indian Government, on its part has taken initiatives to reduce drug prices, has made certain reforms in the tax structure and has undertaken various control programmes. The market is expected to exhibit steady growth over the next few years.

The report begins with the introduction section which offers a brief insight into the major cardiovascular drug classes. It then moves to the market overview section which provides an insight into the global market and then moves on to the Indian market, highlighting the market size and growth.

An analysis of the drivers explains the factors for growth of the industry including increasing patient population, patent expiry of blockbuster drugs, increase in disposable income and introduction of newer and better drugs. The key challenges include strong competition between the different pharma companies and competition from complementary and alternative medicines.

The government initiatives section gives analyses the efforts to reduce drug prices, changes in the customs duty structure and the various control programmes undertaken by the Government.

A brief overview of the drug market value chain, drug regulations and patents is presented in the next section. It analyses the pharmaceutical value chain, and focuses on the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. A snapshot of different regulatory frameworks existing in the Indian pharma industry has been provided. The section also provides a list of important patent approvals for cardiovascular drugs.

The competition section gives overview of pharmaceutical companies in the country operating in the cardiovascular pharmaceutical industry. Thereafter, the report highlights the features of the major players operating in the market in detail. It includes elaborate profile of the major players in the market along with their financial analysis. Porters Five Forces Analysis has been incorporated for a brief but effective understanding of the market scenario. It also incorporates the recent developments in the Cardiovascular Pharmaceutical industry.

The strategic recommendations section focuses on some effective strategic decisions which can be taken up by companies to increase their market shares. The strategic recommendations section focuses on some effective strategic decisions which can be taken up by companies to increase their market shares. Foray into the preventive care therapeutic segment will help the companies gain a competitive advantage over the others. Companies can focus on development of such cardiovascular drugs which can be used as preventive medicines, but without any side effects. Also, efficient marketing strategies are required to make both the physicians and the patients aware of such preventive medicines.

READ MORE

Scope

Page 1: Executive summary

Introduction

Page 2: Major drug classes of cardiovascular drugs

Market Overview

Page 3: Global Cardiovascular Pharmaceuticals Market-Overview, Size & Growth (Value: 2009-15e),

Page 4: Indian Cardiovascular Pharmaceuticals Market- Overview, Size & Growth (Value: 2010-2015e), Growth in Therapeutic segments

Drivers & Challenges

Page 5: Summary

Page 6-9: Drivers

Page 10: Challenges

Government Initiatives

Page 11: Summary

Page 12-13: Government Initiatives

Market value chain, regulation and patents

Page 14: Pharmaceutical value chain

Page 15: Phases of clinical trials

Page16-17: Drug regulations

Page 18: Regulatory frameworks

Page 19-20: List of patent approvals

Competition

Page 21- Market Competition-Porter's Five Forces Analysis

Page 22- 57: Major public players

Page 58- 69: Major private players

Page 70: Recent Developments

Strategic Recommendation

Page 71: Strategic Recommendations


List Of Figure

Market Overview

1. Cardiovascular Pharmaceutical Market- Global Market Size and Growth (Value wise 2009-2015e)

2. Cardiovascular Pharmaceutical Market-India Market Size and Growth (Value-Wise, 2010-2015e)

3. Top pharmaceutical segments (Percentage wise 2010)

Drivers & Challenges

4. Deaths from CVDs (Value wise 2000-2025e)

5. Coronary heart disease patients (Value wise 2010-2015e)

6. Increasing per capita disposable income ( Value wise 2007-2011)

Competition

7. Financial Snapshot

8. Key Business segments (only Public Players)

9. Key Geographic segments (only Public Players)

Except GlaxoSmithKline Pharmaceuticals Limited


List Of Table

Market Overview

1. Top selling cardiovascular drugs 2010-global market

Drivers & Challenges

2. Patent expiry date of drugs

Market Value Chain, Regulation and Patent

3. Tabular representation of drugs approved in recent past (2009- 2010)

4. Tabular representation of regulatory framework of Indian Pharmaceutical Industry

5. Tabular representation of USFDA patent approvals for cardiovascular drugs

Competition

6. Company profiles (All companies)

a. Company information

b. Products and services

c. Key people

d. Key Financial Performance Indicators

e. Key Ratios

Except for Pfizer Limited

f. Business Highlights

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

1. AstraZeneca Pharma India Limited

2. Aventis Pharma Limited

3. Cipla Limited

4. Dr. Reddy's Laboratories Limited

5. GlaxoSmithKline Pharmaceuticals Limited

6. Lupin Limited

7. Merck Limited

8. Novartis India Limited

9. Pfizer Limited

10. Ranbaxy Laboratories Limited

11. Sun Pharmaceutical Industries Limited

12. Torrent Pharmaceuticals Limited

13. Bristol-Myers Squibb India Private Limited

14. Cadila Pharmaceuticals Limited

15. Intas Pharmaceuticals Limited

16. USV Limited